Corporate Analysis – Haisco Pharmaceutical Group

Haisco Pharmaceutical Group (002653.SZ) has posted a neutral 24‑hour trading cycle, closing at a steady 0 % on Thursday, 22 October 2026. The stock trades at approximately CNY 58.99, supported by a liquidity base of 1.1 billion shares and a market capitalization of CNY 66.1 billion. In the past 24 hours, about CNY 398.8 million of Haisco shares were exchanged, reflecting modest intraday volume against a backdrop of a 9.06 % decline since the end of last month.

Technical Context

  • Moving Average (200 days): CNY 62.38
  • 52‑Week High: CNY 80.83 (07 June 2026)
  • 52‑Week Low: CNY 42.38 (03 April 2026)

The current price sits roughly 5.6 % below the 200‑day moving average, indicating a modestly bearish short‑term trend, yet the firm remains well‑above its 52‑week low. This technical backdrop suggests that while Haisco is experiencing a temporary pullback, the underlying trend is still upward relative to its long‑term valuation.

Strategic Outlook

In a recent earnings outlook release, Haisco projected a marked earnings lift for the first three quarters of 2026. The company attributes this upside primarily to:

  1. Domestic Sales Momentum – Continued penetration of its hepatobiliary, anti‑infective, and nutrition drug lines across China, backed by an expanding distribution network.
  2. International Licensing Agreements – Up‑front payments from several overseas partners, providing a cash inflow that offsets the higher R&D outlays.
  3. R&D Efficiency – Although R&D spending has increased, the company maintains a strong net‑profit trajectory, suggesting effective cost management and a focus on high‑margin products.

These drivers align with a broader sectoral shift where Chinese biotech firms are transitioning from R&D to commercialization, thereby justifying higher valuations and accelerating global market entry.

Market Positioning

Haisco’s portfolio spans hepatobiliary, anti‑infective, and nutrition therapeutics—sectors that have seen robust demand amid aging demographics and rising chronic disease prevalence. The company’s manufacturing capabilities, combined with its strategic licensing agreements, position it well to capture both domestic and international revenue streams.

Comparative Stock Performance

  • Rockchip Electronics L – Flat trading, reinforcing its AI and robotics strategy.
  • Eastroc Beverage -H – Down 3.92 %, reflecting broader beverage sector volatility.
  • Power Construction Of – Flat trading, no new data.
  • Guangxi Guiguan Electric – Flat trading, stable in the power equipment space.
  • Li Auto – Up 0.39 %, buoyed by strong leasing activity and EBITDA guidance.

Forward‑Looking Perspective

The confluence of domestic market strength, strategic licensing inflows, and disciplined R&D spending positions Haisco to capitalize on the next wave of biotech commercialization in China. Investors should watch for:

  • Earnings Release: Confirmation of the projected earnings lift in Q3 2026.
  • Licensing Deals: New agreements that may further diversify revenue.
  • Regulatory Approvals: Any expedited approvals for key products, which could accelerate cash flow.

Given its current valuation relative to peers and a solid technical support level, Haisco remains a compelling play for investors seeking exposure to China’s evolving pharmaceutical landscape.